<div id="readability-page-1"><p>Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given a consensus rating of &#34;Moderate Buy&#34; by the five research firms that are  covering the company, Marketbeat.com reports. One research analyst  has rated the stock with a hold recommendation and four have given a buy recommendation to  the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.50.</p><div><p><span></span><span>Get <strong>Amneal Pharmaceuticals</strong> alerts:</span></p></div><ul><li>3 Lesser-Known Healthcare Names With Major Upside in Store</li></ul><p>AMRX has been the subject of several research reports. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an &#34;overweight&#34; rating and a $15.00 price target for the company. Piper Sandler  restated an &#34;overweight&#34; rating and issued a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Finally, JPMorgan Chase &amp; Co. upped their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, September 16th.</p><p><b>Read Our Latest Research Report on AMRX</b></p><h2>Insider Activity at Amneal Pharmaceuticals</h2><ul><li>6 reasons to buy Teva Pharmaceuticals stock sooner than later </li></ul><p>In other news, Director Ted C. Nark sold 50,000 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director directly owned 291,029 shares of the company's stock, valued at $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, EVP Nikita Shah sold 131,856 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the completion of the sale, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 231,856 shares of company stock valued at $2,743,724. 26.56% of the stock is owned by insiders. </p><h2>Institutional Investors Weigh In On Amneal Pharmaceuticals</h2><p>Several hedge funds have recently bought and sold shares of the stock. Mirabella Financial Services LLP purchased a new stake in shares of  Amneal Pharmaceuticals during the 3rd quarter valued at about $147,000.  Tudor Investment Corp ET AL purchased a new stake in  Amneal Pharmaceuticals during the third quarter valued at approximately $921,000.  CIBC Bancorp USA Inc. bought a new position in  Amneal Pharmaceuticals in the third quarter worth approximately $161,000.  Danske Bank A S bought a new position in  Amneal Pharmaceuticals in the third quarter worth approximately $1,092,000.  Finally, Advisory Services Network LLC bought a new stake in  Amneal Pharmaceuticals during the third quarter valued at about $50,000. 31.82% of the stock is currently owned by institutional investors. </p><h2>Amneal Pharmaceuticals Stock Performance</h2><p>Shares of NASDAQ:AMRX opened at $12.96 on Thursday. The company has a market capitalization of $4.07 billion, a P/E ratio of 648.07 and a beta of 1.36. The company's 50-day moving average is $11.63 and its 200 day moving average is $9.88. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $12.98. </p><p>Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.05. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS.  As a group, research analysts predict that  Amneal Pharmaceuticals will post 0.53 earnings per share for the current year. </p><h2>About Amneal Pharmaceuticals</h2> (Get Free Report)<p>Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments. </p><p>Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&amp;A.</p><h2>Read More</h2><ul><li>Five stocks we like better than Amneal Pharmaceuticals</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1SWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1SWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amneal Pharmaceuticals Right Now?</h2><p>Before you consider Amneal Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.</p><p>While Amneal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMRX

<p>Amneal Pharmaceuticals (NASDAQ:AMRX) has received a "Moderate Buy" consensus rating from five research firms, with an average 12-month price target of $13.50. Analysts have given mixed ratings, with some upgrading their price objectives. Insider trading activity includes significant stock sales by company executives. Institutional investors have been active, with several new stakes acquired. The stock opened at $12.96, with a market cap of $4.07 billion. Recent earnings exceeded expectations, and the company has set FY 2025 guidance at 0.750-0.80 EPS.</p>

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts